Nippon Shinyaku Co Ltd - Company Profile
Powered by 
All the data and insights you need on Nippon Shinyaku Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Nippon Shinyaku Co Ltd Strategy Report
- Understand Nippon Shinyaku Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Nippon Shinyaku Co Ltd (Nippon Shinyaku) develops, manufactures and markets ethical pharmaceuticals and functional foods. The company offers drugs for the treatment of contemporary diseases including cardiovascular, gastrointestinal, urological, inflammatory and allergic diseases.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Nippon Shinyaku's R&D efforts focus on advancing its pipeline candidates to address the unmet medical need of urological, hematological, and intractable rare diseases and conditions. The company harnesses its unique drug discovery methods to discover novel drugs and advance its clinical studies. The company is investigating its Phase III clinical candidates: NS-065/NCNP-01 (viltolarsen) for the treatment of Duchenne muscular dystrophy. Nippon Shinyaku is evaluating its Phase II candidates: NS-304 (selexipag) for the treatment of arteriosclerosis obliterans, pediatric pulmonary arterial hypertension and lumbar spinal stenosis; NS-018 (ilginatinib) for the treatment of myelofibrosis; NS-580 for the treatment of endometriosis; and Phase I/II candidate for NS-87 for the treatment of secondary acute myeloid leukemia. It is also investigating NS-917 in pre-Phase I studies for relapsed/refractory acute myeloid leukemia; development of NS-401 (tagraxofusp) for the treatment of blastic plasmacytoid dendritic cell neoplasm; Phase I studies of NS-229 for the treatment of inflammatory diseases. The R&D expenses of the company amounted to JPY24,135 million in FY2023, which grew 5.6% YoY, and as a percentage of revenue stood at 16.7%.
Business Segments
Overview
-Develops, produces, and sells functional food ingredients. -Offers a wide range of functional food products which include protein preparations, preservatives, seasonings and spices and health food materials to address the requirements of processed food and health food manufacturers.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
-Offers a variety of drugs for urological, cardiovascular and metabolic diseases, hematologic malignancies, gastrointestinal disorders, inflammatory and allergic diseases, pain, and gynecological diseases. -Drugs for urological diseases include Zalutia, for urinary disorder; Cialis, for erectile dysfunction; Estracyt, for prostate cancer; Bladderon, for pollakisuria; and Eviprostat, for benign prostatic hypertrophy. -Drugs for hematologic malignancies include Cylocide, remedy for solid tumor and acute leukemia; Amnolake, remedy for relapsed and refractory acute promyelocytic leukemia; Trisenox, remedy for relapsed and refractory acute promyelocytic leukemia; and Vidaza, remedy for Myelodysplastic syndromes. -Drugs for inflammation, pain and allergy include Azunol Gargle liquid, gargling solution containing azulene; Livostin, remedy for allergic rhinitis and conjunctivitis; Baynas, rmedy for allergic rhinitis; Hypen, non-steroidal anti-inflammatory and analgesic agent; Tramal, remedy for cancer pain and Erizas, dry powder inhaler for allergic rhinitis. -Drugs for cardiovascular and metabolic diseases include Selectol, vasodilating beta-1 blocker; and Adcirca, phosphodiesterase. Drugs for gynecological diseases include Lunabell, remedy for dysmenorrhea resulting from endometriosis and functional dysmenorrhea. -Deems new product launches and strategic agreements as the major growth drivers .
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer